JD Health (Stock Codes: 6618 (HKD counter) and 86618 (RMB counter)) reported unaudited revenue of RMB17,119,726 thousand for the third quarter of 2025, reflecting a 28.7% increase from the same period in 2024. Operating income rose by 125.3% year on year to RMB1,243,290 thousand, while non-IFRS operating income grew 59.9% to RMB1,377,755 thousand. Profit for the quarter reached RMB1,838,503 thousand, representing a 97.2% year-on-year increase, and non-IFRS profit was RMB1,902,237 thousand, up 42.4% over the previous year.

During the quarter, JD Health entered into strategic cooperation agreements with several major pharmaceutical companies, including Eli Lilly, Innovent Biologics, Eisai China, and Bayer China. The company continued to expand its portfolio by debuting new medicines, such as Eisai’s DAYVIGO (Lemborexant Tablets), Hengrui Pharma’s Heng Qin (Perfluorohexyloctane Eye Drops), and Bayer’s Talcid Lactulose. It also introduced nutrition and health supplement products, including Haleon’s latest Centrum Silver vitamins and Sainte’s Teai Benjia formula.

In September 2025, JD Health formed an alliance with Yuwell, Sinocare, and MicroTech to develop an intelligent, full-cycle blood glucose management ecosystem, aiming to integrate monitoring, analysis, intervention, and tracking. The company further partnered with Union Hospital of Huazhong University of Science and Technology’s Tongji Medical College to establish an intelligent outpatient service platform. Both parties plan to apply JD Health’s “JOY DOC” AI products in offline hospital scenarios, with the goal of creating a more efficient and convenient medical experience.

The financial figures provided are based on the Board’s preliminary review of internal data and have not been audited. They are subject to possible changes or adjustments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.